CORE Biomedicine, Inc. Named Finalist in the 2025 Harvard Presidents Innovation Challenge
Boston, MA — Mar 27, 2025 — CORE Biomedicine, Inc. is proud to announce that it has been selected as an official Finalist in the prestigious 2025 Harvard Presidents Innovation Challenge. This recognition highlights CORE Biomedicine’s commitment to pioneering advancements in biomedical innovation and its potential to transform patient outcomes on a global scale.
The Harvard Presidents Innovation Challenge is one of the nation’s leading university innovation competitions, celebrating exceptional entrepreneurship and breakthrough technologies from teams across various business sectors. CORE Biomedicine’s distinction as a finalist places the company among an elite group of innovators driving meaningful progress in health and science.
“We are honored to be recognized by Harvard’s Innovation Labs and to stand among such visionary entrepreneurs,” said Dr. Ping Zhu, Co-founder and CEO of CORE Biomedicine, Inc. “This milestone reflects the dedication of our team and strengthens our mission to bring transformative biomedical solutions to patients and healthcare providers.”
Read more about the Harvard President’s Innovation Challenge here: https://innovationlabs.harvard.edu/presidents-innovation-challenge
CORE Biomedicine continues to push the boundaries of biomedical research and development with precision medicine 2.0 approaches to discover and develop first-in-class and best-in-class targets for oncology. Being named a finalist in this esteemed competition underscores both the innovation and real-world potential of the company’s efforts.
About CORE Biomedicine, Inc.
Founded by the former leadership of H3 Biomedicine, CORE Biomedicine, Inc. is building the next wave of oncology innovation by going beyond precision medicine. CORE’s lineage-based therapeutic platform targets the fundamental biological programs that define cancer cell identity, enabling the discovery of first- and best-in-class medicines with the potential to reach significantly larger patient populations.
Contact: contact@corebiomedicine.com